Compare SPSC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPSC | GLPG |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2009 | N/A |
| Metric | SPSC | GLPG |
|---|---|---|
| Price | $53.58 | $27.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $96.80 | $36.50 |
| AVG Volume (30 Days) | ★ 443.6K | 139.8K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.59 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $220,566,000.00 | N/A |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | $7.37 | N/A |
| P/E Ratio | $98.96 | ★ N/A |
| Revenue Growth | ★ 14.11 | N/A |
| 52 Week Low | $49.04 | $26.62 |
| 52 Week High | $147.61 | $37.78 |
| Indicator | SPSC | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 36.53 |
| Support Level | $51.52 | N/A |
| Resistance Level | $59.73 | $34.04 |
| Average True Range (ATR) | 2.57 | 0.56 |
| MACD | -0.12 | 0.08 |
| Stochastic Oscillator | 43.84 | 25.33 |
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. The company has one operating segment Supply Chain Management Solutions, that derives revenues from customers by providing access to cloud-based supply chain management services, primarily under subscription-based service arrangements.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.